Literature DB >> 8795379

Protective role of nitric oxide in ocular toxoplasmosis.

S Hayashi1, C C Chan, R T Gazzinelli, N T Pham, M K Cheung, F G Roberge.   

Abstract

AIMS: To evaluate the role of nitric oxide (NO) in ocular involvement during systemic toxoplasmosis.
METHODS: C57B1/6 mice were infected with Toxoplasma gondii strain ME49. The synthesis of NO was inhibited by an intraperitoneal injection of aminoguanidine every 8 hours, starting on the day of infection. Control infected mice received phosphate buffered saline vehicle alone. After 14 days, the ocular lesions were evaluated by histopathological examination. The expression of NO synthase induced in the spleen by toxoplasma infection was evaluated by immunostaining. The production of NO by the spleen cells of infected mice was measured by the colorimetric assay of Griess in the supernatant of cultures stimulated with toxoplasma antigen or concanavalin A.
RESULTS: The inhibition of NO production in T gondii infected mice resulted in a marked increase in the symptoms of ocular inflammation. We observed a strong induction of NO synthase expression in the spleen of infected animals. In culture, the spleen cells from these mice produced high levels of NO in response to T gondii antigens. This elevation of NO synthesis was suppressed in the presence of aminoguanidine.
CONCLUSION: This study indicates that NO plays a crucial role in the protection against T gondii infection as reflected by the severity of the ocular involvement.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8795379      PMCID: PMC505561          DOI: 10.1136/bjo.80.7.644

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  37 in total

1.  Editorial: Dangers of steroid treatment in toxoplasmosis. Periocular injections and systemic therapy.

Authors:  G R O'Connor; J K Frenkel
Journal:  Arch Ophthalmol       Date:  1976-02

2.  Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome.

Authors:  H W Murray; B Y Rubin; H Masur; R B Roberts
Journal:  N Engl J Med       Date:  1984-04-05       Impact factor: 91.245

3.  Ocular toxoplasmosis in an adult receiving long-term corticosteroid therapy.

Authors:  D H Nicholson; E B Wolchok
Journal:  Arch Ophthalmol       Date:  1976-02

4.  Toxoplasmic retinochoroiditis: electron-microscopic and immunofluorescence studies of formalin-fixed tissue.

Authors:  N A Rao; R L Font
Journal:  Arch Ophthalmol       Date:  1977-02

5.  Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages.

Authors:  D L Granger; J B Hibbs; J R Perfect; D T Durack
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

6.  Diffuse toxoplasmic retinochoroiditis in a patient with AIDS.

Authors:  D W Parke; R L Font
Journal:  Arch Ophthalmol       Date:  1986-04

7.  Interferon-gamma: the major mediator of resistance against Toxoplasma gondii.

Authors:  Y Suzuki; M A Orellana; R D Schreiber; J S Remington
Journal:  Science       Date:  1988-04-22       Impact factor: 47.728

8.  Macrophage oxygen-dependent antimicrobial activity. I. Susceptibility of Toxoplasma gondii to oxygen intermediates.

Authors:  H W Murray; Z A Cohn
Journal:  J Exp Med       Date:  1979-10-01       Impact factor: 14.307

9.  Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages.

Authors:  J Chan; Y Xing; R S Magliozzo; B R Bloom
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

10.  Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates.

Authors:  H W Murray; C W Juangbhanich; C F Nathan; Z A Cohn
Journal:  J Exp Med       Date:  1979-10-01       Impact factor: 14.307

View more
  9 in total

1.  A patatin-like protein protects Toxoplasma gondii from degradation in activated macrophages.

Authors:  Dana G Mordue; Casey F Scott-Weathers; Crystal M Tobin; Laura J Knoll
Journal:  Mol Microbiol       Date:  2006-12-11       Impact factor: 3.501

2.  Rabies virus ocular disease: T-cell-dependent protection is under the control of signaling by the p55 tumor necrosis factor alpha receptor, p55TNFR.

Authors:  S Camelo; J Castellanos; M Lafage; M Lafon
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Immunological studies of chronic ocular toxoplasmosis: up-regulation of major histocompatibility complex class I and transforming growth factor beta and a protective role for interleukin-6.

Authors:  R E Lyons; J P Anthony; D J Ferguson; N Byrne; J Alexander; F Roberts; C W Roberts
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  IL-33/ST2 involves the immunopathology of ocular toxoplasmosis in murine model.

Authors:  Xinxin Tong; Fangli Lu
Journal:  Parasitol Res       Date:  2015-02-20       Impact factor: 2.289

Review 5.  Toxoplasma gondii: determinants of tachyzoite to bradyzoite conversion.

Authors:  Sini Skariah; Matthew Karmen McIntyre; Dana G Mordue
Journal:  Parasitol Res       Date:  2010-06-01       Impact factor: 2.289

Review 6.  Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections.

Authors:  Philip M Bath; Christopher M Coleman; Adam L Gordon; Wei Shen Lim; Andrew J Webb
Journal:  F1000Res       Date:  2021-07-05

Review 7.  CD40 and the immune response to parasitic infections.

Authors:  Carlos S Subauste
Journal:  Semin Immunol       Date:  2009-07-18       Impact factor: 11.130

8.  The protein kinase double-stranded RNA-dependent (PKR) enhances protection against disease cause by a non-viral pathogen.

Authors:  Pauline Sebby Ogolla; Jose-Andres C Portillo; Christine L White; Krupen Patel; Bruce Lamb; Ganes C Sen; Carlos S Subauste
Journal:  PLoS Pathog       Date:  2013-08-22       Impact factor: 6.823

9.  c-Src kinase is involved in the tyrosine phosphorylation and activity of SLC11A1 in differentiating macrophages.

Authors:  Yong Zhong Xu; Thusanth Thuraisingam; Cynthia Kanagaratham; Shao Tao; Danuta Radzioch
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.